ONCT-534 recruiting
ONCT-534 Earns FDA Fast Track Designa... - Advanced Prostate...
ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC
Written by
Maxone73
To view profiles and participate in discussions please or .
5 Replies
•
Thanks. Their is still hope.
According to findings from preclinical studies, the agent has demonstrated activity in prostate cancer models with and without AR mutations.
Does not say what the basis for fast track is. Could it be more than mouse models?
it's for investigational drugs development, I thought it would happen after an incredibly promising start of phase 1, but it seems that the potential and the fact that it would be a lifesaver can be enough
from what I read they will sun a phase 1/2 instead of two separate phases
Good Luck, Good Health and Good Humor.
j-o-h-n Monday 10/30/2023 7:45 PM DST
My work of art............Little bastards having fun with my body.
Not what you're looking for?
You may also like...
Another Lu-177 solution gets fast tracked: Lu-177-DGUL, secures 'GIFT' designation
from its “Global Innovative Products on Fast Track” (GIFT) program, signifying a significant...
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
the FDA. The article has the basic results of the ARASENS trial.
https://www.onclive.com/view/fda
ONCT-534 some trial data soon?
The company developing ONCT-534 will take part at Oppenheimer 34th Annual Healthcare Life Sciences
Marijuana use may be associated with reduced prevalence of prostate cancer - cross sectional study
https://doi.org/10.1200/JCO.2024.42.4_suppl.
The study seems quite small
“Results: Prevalence of
Help with choosing treatment pathway
Diagnosed March 2020 with Stage 4 high volume metastatic prostate cancer. Gleason score 9 (4+5),...